menu
    • menu
    [{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"B. Braun Medical | European Society of Anaesthesiology and Intensive Care","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Carbohydrate","year":"2017","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Hematology","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ B. Braun Medical | European Society of Anaesthesiology and Intensive Care","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ B. Braun Medical | European Society of Anaesthesiology and Intensive Care"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"B. Braun Medical | European Society of Anaesthesiology and Intensive Care","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SWEDEN","productType":"Carbohydrate","year":"2017","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Hematology","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Fresenius Kabi AB Brunna \/ B. Braun Medical | European Society of Anaesthesiology and Intensive Care","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ B. Braun Medical | European Society of Anaesthesiology and Intensive Care"},{"orgOrder":0,"company":"Fresenius Kabi AB Brunna","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWEDEN","productType":"Carbohydrate","year":"2012","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Fresenius Kabi AB Brunna","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Kabi AB Brunna \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Kabi AB Brunna \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Carbohydrate","year":"2010","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Kabi AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Kabi AG \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"B. Braun Medical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Carbohydrate","year":"2011","type":"Inapplicable","leadProduct":"Hydroxyethyl Starch","moa":"Plasma volume","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"B. Braun Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"B. Braun Medical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"B. Braun Medical \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Hydroxyethyl Starch

    Menu

    Hydroxyethyl Starch

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fresenius Kabi AB Brunna

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fresenius Kabi AB Brunna

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : B. Braun Medical | European Society of Anaesthesiology and Intensive Care

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patien...

                            Details : Volulyte (Hydroxyethyl Starch) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.

                            Product Name : Volulyte

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            November 09, 2017

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : B. Braun Medical | European Society of Anaesthesiology and Intensive Care

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Fresenius Kabi AB Brunna

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fresenius Kabi AB Brunna

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : B. Braun Medical | European Society of Anaesthesiology and Intensive Care

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Underg...

                            Details : Volulyte (Hydroxyethyl Starch) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemorrhage.

                            Product Name : Volulyte

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            September 11, 2017

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : B. Braun Medical | European Society of Anaesthesiology and Intensive Care

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fresenius Kabi AB Brunna

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fresenius Kabi AB Brunna

                            Sweden arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            VolulyteTM in Cardiac Surgery

                            Details : Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Heart Failure.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            March 14, 2012

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rambam Health Care Campus

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Effectiveness of a Balanced 3rd Generation HES Solution (Tetraspan®) After Cardiac Surgery

                            Details : Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            August 17, 2011

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            B. Braun Medical

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            B. Braun Medical

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of HES 130 in Balanced and in Unbalanced Solution

                            Details : Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Blood Pressure Disorders.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            February 23, 2011

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Fresenius Kabi AG

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fresenius Kabi AG

                            Germany arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Obtain Volume Effect and Safety Data on 6 % Hydroxyethyl Starch 130/0.4 in Pediatric and Adult Patien...

                            Details : Hydroxyethyl Starch is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hypovolemia.

                            Product Name : Undisclosed

                            Product Type : Carbohydrate

                            Upfront Cash : Inapplicable

                            May 21, 2010

                            Lead Product(s) : Hydroxyethyl Starch

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth